Investor Presentaiton
For personal use only
TLX250-CDx: delivering an unmet need in kidney cancer imaging
Estimated age-standardized incidence rates (World) in 2020, kidney, both sexes, all ages
Total addressable
market value in US
and Europe estimated
at US$300-400M1
Potential for market
leadership, given
limited patient options
Addresses a major
unmet medical need
for more accurate
patient staging
ASR (World) per 100 000
≥ 7.5
3.5-7.5
2.2-3.5
1.2-2.2
< 1.2
Yearly new cases,
worldwide, both
sexes, all ages
431,288
Not applicable
No data
Yearly estimated
number of deaths,
worldwide, both
sexes, all ages
179,368
All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever
on the part of the World Health Organization / International Agency for Research on Cancer concerning the legal status of any country, territory, city or area
or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate borderlines for
which there may not yet be full agreement.
Data source: GLOBOCAN 2020
Graph production: IARC
(http://gco.iarc.fr/today)
World Health Organization
1. Management estimate based on Globocan reported incidence; (Globocan 2020)
Dollar ($) TAM values are management estimates based on Globocan reported incidence x estimated unit cost per dose.
Telix Pharmaceuticals Limited (ASX: TLX)
TELIX
PHARMACEUTICALS
World Health
Organization
International Agency for
Research on Cancer 2021
41View entire presentation